Cargando…

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid

In a previous study, obeticholic acid (OCA) increased liver growth before partial hepatectomy (PHx) in rats through the bile acid receptor farnesoid X-receptor (FXR). In that model, OCA was administered during obstructive cholestasis. However, patients normally undergo PHx several days after biliary...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Haan, Lianne R., Verheij, Joanne, van Golen, Rowan F., Horneffer-van der Sluis, Verena, Lewis, Matthew R., Beuers, Ulrich H. W., van Gulik, Thomas M., Olde Damink, Steven W. M., Schaap, Frank G., Heger, Michal, Olthof, Pim B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916678/ https://www.ncbi.nlm.nih.gov/pubmed/33578971 http://dx.doi.org/10.3390/biom11020260

Ejemplares similares

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers
por: Wiggers, Jimme K., et al.
Publicado: (2017)

Simple steatosis sensitizes cholestatic rats to liver injury and dysregulates bile salt synthesis and transport
por: Lionarons, Daniël A., et al.
Publicado: (2016)

Effect of Plasmapheresis on Cholestatic Pruritus and Autotaxin Activity During Pregnancy
por: Heerkens, Marieke, et al.
Publicado: (2019)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

IL-23 and IL-17A are not involved in hepatic/ischemia reperfusion injury in mouse and man
por: Olthof, Pim B., et al.
Publicado: (2015)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
por: Attia, Yasmeen M., et al.
Publicado: (2017)

Analysis and Optimization of Conditions for the Use of 2′,7′-Dichlorofluorescein Diacetate in Cultured Hepatocytes
por: Reiniers, Megan J., et al.
Publicado: (2021)

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
por: Zhang, Dan-Ying, et al.
Publicado: (2019)

FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease
por: Koelfat, Kiran V.K., et al.
Publicado: (2017)

ASO Author Reflections: Essential to Reduce Adverse Outcomes in Perihilar Cholangiocarcinoma Surgery—Portal Vein Embolization
por: Olthof, Pim B., et al.
Publicado: (2020)

The Simple Cholestatic Complaints Score is a valid and quick patient‐reported outcome measure in primary sclerosing cholangitis
por: van Munster, Kim N., et al.
Publicado: (2020)

The Role of Farnesoid X Receptor in Accelerated Liver Regeneration in Rats Subjected to ALPPS
por: Daradics, Noemi, et al.
Publicado: (2021)

Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
por: Szalowska, Ewa, et al.
Publicado: (2013)

Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR
por: Dong, Bin, et al.
Publicado: (2019)

Preparation and Practical Applications of 2′,7′-Dichlorodihydrofluorescein in Redox Assays
por: Reiniers, Megan J., et al.
Publicado: (2017)

Experimental Conditions That Influence the Utility of 2′7′-Dichlorodihydrofluorescein Diacetate (DCFH(2)-DA) as a Fluorogenic Biosensor for Mitochondrial Redox Status
por: de Haan, Lianne R., et al.
Publicado: (2022)

The use of a NHS-PEG coated, collagen-based sealant in a patient undergoing Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS)
por: Olthof, Pim B., et al.
Publicado: (2018)

Post-hepatectomy liver regeneration in the context of bile acid homeostasis and the gut-liver signaling axis
por: de Haan, Lianne, et al.
Publicado: (2018)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

A Clinical Perspective on the Criteria for Liver Resection and the Use of Liver Function Tests
por: Heger, Michal, et al.
Publicado: (2009)

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Impact of Global Fxr Deficiency on Experimental Acute Pancreatitis and Genetic Variation in the FXR Locus in Human Acute Pancreatitis
por: Nijmeijer, Rian M., et al.
Publicado: (2014)

Gut Microbes Take It to the Next Level? First Insights Into Farnesoid X Receptor Agonists of Microbial Origin
por: Lenicek, Martin, et al.
Publicado: (2020)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Paeoniflorin Protects against ANIT-Induced Cholestatic Liver Injury in Rats via the Activation of SIRT1-FXR Signaling Pathway
por: Chen, Lisheng, et al.
Publicado: (2021)

The role of bile salts in liver regeneration
por: van de Laarschot, Liyanne F. M., et al.
Publicado: (2016)

Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells
por: Weijer, Ruud, et al.
Publicado: (2015)

Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders
por: Appelman, Monique D., et al.
Publicado: (2021)

Platelet aggregation but not activation and degranulation during the acute post-ischemic reperfusion phase in livers with no underlying disease
por: van Golen, Rowan F., et al.
Publicado: (2015)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

SERCA2a Protein Levels Are Unaltered in Human Heart Failure
por: Ragone, Isabella, et al.
Publicado: (2023)

Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population‐based study from 1993 to 2017
por: van Doeveren, Thomas, et al.
Publicado: (2021)

Functional assessment of liver regeneration after major hepatectomy
por: Rassam, Fadi, et al.
Publicado: (2022)

Kinsenoside Alleviates 17α-Ethinylestradiol-Induced Cholestatic Liver Injury in Rats by Inhibiting Inflammatory Responses and Regulating FXR-Mediated Bile Acid Homeostasis
por: Ming, Jiaxiong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aisi9pp42cdplh7tad6fe42f2k